Drug Profile
TRC 694
Alternative Names: JNJ-64290694Latest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator Janssen Pharmaceutica
- Developer TRACON Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action NF kappa B kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (PO)
- 28 Feb 2019 TRACON returns rights of TRC 694 to Janssen following completion of pre-clinical development
- 10 May 2017 TRACON announces intention to submit IND for TRC 694 by 2018